Gut Microbiota and Pediatric Eye Diseases: Current Insights, Mechanistic Underpinnings, and Future Outlook

Why It Matters

Early microbial disturbances could set a trajectory for lifelong visual health, making gut‑targeted prevention a potential game‑changer for pediatric ophthalmology.

Key Takeaways

• Allergic conjunctivitis linked to reduced Bifidobacterium and Lactobacillus levels
• Myopic children show lower gut diversity and SCFA‑producing bacteria
• Preterm infants with ROP exhibit dysbiosis, higher Clostridia, lower Bacteroidetes
• Probiotic trials suggest reduced inflammation but lack large‑scale validation
• Gut‑derived metabolites like SCFAs and 3‑IAA modulate ocular growth pathways

Pulse Analysis

The concept of a gut‑eye axis is gaining traction as researchers uncover how intestinal microbes influence ocular development. In children, the gut microbiome matures rapidly within the first three years, a period that coincides with critical windows for visual system formation. Recent cohort studies have identified specific microbial signatures—such as decreased Bifidobacterium in allergic conjunctivitis or reduced Akkermansia in high‑myopia patients—suggesting that early dysbiosis may predispose to ocular inflammation and abnormal axial growth. These findings extend the well‑established gut‑brain and gut‑lung connections, positioning the microbiome as a systemic regulator of eye health.

Mechanistically, the review highlights four interrelated pathways. Immune regulation is central: dysbiotic communities impair regulatory T‑cell development, skewing toward Th2 responses that exacerbate allergic eye disease. Metabolites like short‑chain fatty acids and indole‑3‑acetic acid (3‑IAA) provide anti‑inflammatory signals and support collagen synthesis, directly affecting retinal vascularization and scleral remodeling. Barrier crosstalk allows microbial products to breach the intestinal wall, triggering systemic cytokine release that can compromise the blood‑ocular barrier. Emerging evidence also points to a gut‑brain‑eye neural circuit, though direct pediatric data remain sparse.

Clinically, the translation of these insights faces significant hurdles. Most studies are cross‑sectional, involve small cohorts, and lack standardized probiotic formulations or dosing regimens. Nonetheless, early probiotic administration in preterm infants shows promise for reducing systemic inflammation linked to ROP, while dietary interventions that boost SCFA‑producing bacteria could become adjuncts in myopia control. The authors urge large‑scale, longitudinal trials and the development of microbial biomarkers to enable risk stratification and personalized therapy. By integrating microbiome assessment into pediatric eye care, clinicians may soon have novel tools to prevent or mitigate vision‑threatening conditions from the earliest stages of life.